Gilead withdraws use of Zydelig to treat two types of cancer


Bywire - Claim your free account nowBywire - love news, hate ads?

- Gilead Sciences Inc has notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia.

(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)

Bywire will email you from time to time with news digests, stories & opportunities to get involved. Privacy

Bywire - Claim your free account nowBywire - love news, hate ads?